Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Assessment of the safety of hypoxia-primed mesenchymal stem cells derived from umbilical cord and adipose tissues in animals.

Dinh NT., Nguyen QT., Hang NT., Dao HN., Son LD., Ngan GT.

Animal Study on Systemic / IV, published in Sci Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Sci Rep (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41094014
DOI
10.1038/s41598-025-20018-5

Abstract (original English)

Mesenchymal stem cells (MSCs) are widely used for disease treatment, typically cultured in ambient oxygen (21%) exceeding physiological levels (2-5%). While hypoxic MSCs show in vitro advantages, their in vivo effects remain less understood. This study evaluated the safety of xeno-free, serum-free cultured MSCs from adipose tissue (AD-MSCs) and umbilical cords (UC-MSCs) primed with 5% oxygen in healthy rabbits, Swiss mice, and rats. Assessments included vascular and muscle stimulation, systemic hypersensitivity, acute toxicity, and subchronic toxicity. Our data indicated that the injection of UC-MSCs induced vascular stimulation but not muscular stimulation, whereas the injection of AD-MSCs caused neither vascular nor muscular stimulation. Additionally, neither AD-MSCs nor UC-MSCs affected hematopoietic parameters (white blood cell, red blood cell, platelet, or hemoglobin levels), altered the levels of proinflammatory cytokines (IL-6, IL-1β, IFN-γ, and TNF-a), or induced allergenic responses in rabbits. Furthermore, intravenous injection of either UC-MSCs or AD-MSCs at a dose of 50 × 10 6 cells/kg did not cause acute toxicity in mice. However, injections of higher doses of these cells led to intravenous thrombosis and embolism in various organs of experimental animals, ultimately resulting in animal death. Finally, according to the subchronic toxicity assay, the administration

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMesenchymal Stem CellsRabbitsAdipose TissueUmbilical CordRatsMiceMesenchymal Stem Cell TransplantationMaleCell Hypoxia

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research